Capricor Therapeutics Inc (NASDAQ:CAPR) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) have been given an average rating of “Buy” by the six brokerages that are presently covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $34.50.

Several research analysts have recently weighed in on CAPR shares. Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 price target on shares of Capricor Therapeutics in a report on Monday, September 23rd. Piper Sandler initiated coverage on Capricor Therapeutics in a report on Monday, October 21st. They issued an “overweight” rating and a $35.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a report on Thursday, November 14th. Cantor Fitzgerald raised their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. Finally, Maxim Group boosted their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th.

Institutional Trading of Capricor Therapeutics

Hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC raised its stake in shares of Capricor Therapeutics by 158.7% during the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after acquiring an additional 84,350 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Capricor Therapeutics during the 2nd quarter valued at $426,000. Point72 Asset Management L.P. purchased a new position in Capricor Therapeutics in the 3rd quarter worth $3,806,000. The Manufacturers Life Insurance Company bought a new stake in Capricor Therapeutics in the third quarter worth $161,000. Finally, BNP Paribas Financial Markets boosted its position in Capricor Therapeutics by 868.7% during the third quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock valued at $269,000 after buying an additional 15,872 shares during the period. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Trading Down 0.8 %

Capricor Therapeutics stock opened at $14.01 on Thursday. Capricor Therapeutics has a 1-year low of $3.52 and a 1-year high of $23.40. The firm has a market capitalization of $637.03 million, a PE ratio of -13.22 and a beta of 3.98. The firm’s 50 day simple moving average is $17.68 and its 200 day simple moving average is $10.46.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.